Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands. Show more
Location: Ugland House, Grand Cayman, KY1-1104, Cayman Islands | Website: https://www.adlainortye.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
55.96M
52 Wk Range
$1.10 - $4.10
Previous Close
$1.52
Open
$1.52
Volume
272
Day Range
$1.50 - $1.52
Enterprise Value
128.8M
Cash
61.16M
Avg Qtr Burn
-12.95M
Insider Ownership
14.25%
Institutional Own.
0.18%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Buparlisib/AN2025 + Paclitaxel Details Cancer, Head and neck squamous cell carcinoma | Phase 3 Data readout | |
Buparlisib/AN2025 in comb w/chemoradiotherapy and radiotherapy Details Cancer, Rectal cancer | Phase 2 Data readout | |
AN0025 + definitive chemoradiotherapy (dCRT) Details Cancer, Esophageal cancer | Phase 1b Data readout |